查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1714339

胃癌治療市場－全球產業規模、佔有率、趨勢、機會及預測，依治療類型、最終用戶、地區及競爭情況細分，2020-2030 年預測

Gastric Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type, By End User, By Region & Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球胃癌治療市場價值為 39.8 億美元，預計到 2030 年將達到 57 億美元，複合年成長率為 6.12%。胃癌是一種起源於胃黏膜的惡性腫瘤，需要多方面的治療方法，包括手術、化療、放射療法、標靶療法、免疫療法和聯合治療。市場成長主要受到全球胃癌發病率上升的推動，特別是在東亞和拉丁美洲等地區，以及診斷技術和治療創新的進步。提高認知和早期檢測措施有助於獲得更好的臨床結果。精準醫療和基於生物標記的療法的發展也在重塑治療格局。儘管取得了這些進步，但市場仍面臨著治療成本高、治療抵抗力強以及某些地區獲得尖端醫療服務的機會有限等挑戰。儘管如此，持續的研究、製藥公司之間的合作以及以患者為中心的護理策略正在推動市場走向更個人化和有效的治療解決方案。

市場概覽
預測期 2026-2030
2024年市場規模 39.8億美元
2030年市場規模 57億美元
2025-2030 年複合年成長率 6.12%
成長最快的領域 標靶治療
最大的市場 北美洲

關鍵市場促進因素

胃癌發生率上升

主要市場挑戰

晚期治療選擇有限

主要市場趨勢

免疫療法占主導地位

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：胃癌治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依治療類型（化療、標靶治療、免疫治療、放射治療、手術）
    • 按最終使用者（門診手術中心、醫院和專科診所、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第8章：亞太胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：南美胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲胃癌治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 13 章： 大環境分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：全球胃癌治療市場：SWOT 分析

第 16 章：競爭格局

  • Abbott Laboratories Inc.
  • Amgen, Inc.
  • Celltrion Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc.
  • AstraZeneca Plc
  • Pfizer Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 16096

The Global Gastric Cancer Therapy Market was valued at USD 3.98 billion in 2024 and is projected to reach USD 5.70 billion by 2030, growing at a CAGR of 6.12%. Gastric cancer, a malignancy originating in the stomach lining, requires a multifaceted approach to treatment that includes surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combination treatments. Market growth is primarily fueled by the rising global incidence of gastric cancer, particularly in regions such as East Asia and Latin America, as well as advancements in diagnostic techniques and therapeutic innovations. Increasing awareness and early detection initiatives have contributed to better clinical outcomes. Precision medicine and the development of biomarker-based therapies are also reshaping the treatment landscape. Despite these advancements, the market faces challenges such as high treatment costs, resistance to therapy, and limited access to cutting-edge care in certain regions. Nonetheless, continuous research, partnerships among pharmaceutical players, and patient-centered care strategies are propelling the market toward more personalized and effective therapeutic solutions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 3.98 Billion
Market Size 2030USD 5.70 Billion
CAGR 2025-20306.12%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Gastric Cancer

The increasing incidence of gastric cancer is a critical driver of the Global Gastric Cancer Therapy Market. In 2020, over 1.1 million new gastric cancer cases were reported globally, with approximately 770,000 related deaths. The disease is notably more prevalent in males, and Eastern Asia continues to report the highest incidence. Aging populations, lifestyle factors such as smoking and dietary habits, and environmental exposures contribute to the disease's global rise. Regions like Japan, China, South Korea, and parts of Latin America and Europe exhibit particularly high prevalence. In India, for example, northeastern districts like Aizawl and Papumpare have recorded alarmingly high age-adjusted rates. As early detection improves and more cases are diagnosed, the demand for effective treatment options has intensified. This trend is driving the expansion of chemotherapy, immunotherapy, and targeted therapy offerings to meet the growing therapeutic needs of patients worldwide.

Key Market Challenges

Limited Treatment Options for Advanced Stages

Advanced-stage gastric cancer presents a major treatment challenge, largely due to its aggressive progression and resistance to conventional therapies. Once the cancer has metastasized, standard treatments such as chemotherapy, targeted therapies, and immunotherapy may lose efficacy due to genetic mutations and immune evasion mechanisms developed by cancer cells. As a result, treatment outcomes in advanced stages remain limited. Research is increasingly focusing on combination therapies and novel targets to overcome resistance and improve survival rates. Clinical trials are critical in evaluating these innovations and expanding the therapeutic arsenal. However, access to these new treatments is often limited by geographic, economic, and regulatory constraints. Overcoming these hurdles will require coordinated efforts among research institutions, pharmaceutical companies, and regulatory bodies to broaden treatment options and ensure equitable access for patients battling advanced gastric cancer.

Key Market Trends

Immunotherapies Dominance

Immunotherapy is emerging as a dominant force in the Global Gastric Cancer Therapy Market, revolutionizing the traditional treatment approach by leveraging the immune system to fight cancer. Immune checkpoint inhibitors-such as those targeting PD-1, PD-L1, and CTLA-4-have demonstrated remarkable success in treating patients with advanced gastric cancer. These therapies have led to longer survival and improved quality of life for some patients who previously had limited treatment options. Their ability to generate durable immune responses has opened up new possibilities, especially when used in combination with chemotherapy or targeted therapy. However, response rates vary, and immune-related adverse events remain a concern. Ongoing research is focused on identifying biomarkers to better predict patient response, optimizing treatment combinations, and reducing side effects. As clinical evidence grows and regulatory approvals expand, immunotherapies are expected to remain central to the evolving landscape of gastric cancer treatment, driving innovation and offering renewed hope for improved patient outcomes.

Key Market Players

  • Abbott Laboratories Inc.
  • Amgen, Inc.
  • Celltrion Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies Inc.
  • AstraZeneca Plc
  • Pfizer Inc.
  • Eli Lilly & Co.
  • GlaxoSmithKline Plc.

Report Scope:

In this report, the Global Gastric Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gastric Cancer Therapy Market, By Therapy Type:

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Surgery

Gastric Cancer Therapy Market, By End User:

  • Ambulatory Surgery Centers
  • Hospitals and Specialty Clinics
  • Other

Gastric Cancer Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gastric Cancer Therapy Market.

Available Customizations:

Global Gastric Cancer Therapy Market report with the given Market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Gastric Cancer Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery)
    • 5.2.2. By End User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Gastric Cancer Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Gastric Cancer Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Gastric Cancer Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Gastric Cancer Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By End User

7. Europe Gastric Cancer Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Gastric Cancer Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By End User
    • 7.3.2. United Kingdom Gastric Cancer Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By End User
    • 7.3.3. Italy Gastric Cancer Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By End User
    • 7.3.4. France Gastric Cancer Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Gastric Cancer Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By End User

8. Asia-Pacific Gastric Cancer Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Gastric Cancer Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Gastric Cancer Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Gastric Cancer Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Gastric Cancer Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Gastric Cancer Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By End User

9. South America Gastric Cancer Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Gastric Cancer Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By End User
    • 9.3.2. Argentina Gastric Cancer Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By End User
    • 9.3.3. Colombia Gastric Cancer Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By End User

10. Middle East and Africa Gastric Cancer Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Gastric Cancer Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Saudi Arabia Gastric Cancer Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By End User
    • 10.3.3. UAE Gastric Cancer Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Global Gastric Cancer Therapy Market: SWOT Analysis

16. Competitive Landscape

  • 16.1. Abbott Laboratories Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Product & Service Offerings
    • 16.1.3. Recent Developments
    • 16.1.4. Financials (If Listed)
    • 16.1.5. Key Personnel
    • 16.1.6. SWOT Analysis
  • 16.2. Amgen, Inc.
  • 16.3. Celltrion Inc.
  • 16.4. Novartis AG
  • 16.5. F. Hoffmann-La Roche Ltd
  • 16.6. Agilent Technologies Inc.
  • 16.7. AstraZeneca Plc
  • 16.8. Pfizer Inc.
  • 16.9. Eli Lilly & Co.
  • 16.10.GlaxoSmithKline Plc.

17. Strategic Recommendations

18. About Us & Disclaimer